newsThe Phase II clinical trial is the first completed prospective…
30 September 2024 | By Catherine Eckford (European Pharmaceutical Review)
The Phase II clinical trial is the first completed prospective trial for refractory meningiomas with a tumour growth rate of 15 percent or more over six months.